Amit Sachdev - 01 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Patient Officer
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
01 Feb 2023
Net transactions value
$0
Form type
4
Filing time
03 Feb 2023, 15:56:38 UTC
Previous filing
11 Mar 2022
Next filing
14 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Gift $0 -1,672 -13% $0.000000 11,052 17 May 2022 Held in Trust
transaction VRTX Common Stock Award $0 +10,324 +19% $0.000000 63,676 01 Feb 2023 Direct F1
transaction VRTX Common Stock Award $0 +8,210 +13% $0.000000 71,886 01 Feb 2023 Direct F2
transaction VRTX Common Stock Award $0 +7,866 +11% $0.000000 79,752 01 Feb 2023 Direct F3
holding VRTX Common Stock 882 01 Feb 2023 401(k)
holding VRTX Common Stock 8,861 01 Feb 2023 Held in Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023.
F3 Restricted stock unit award that vests in installments beginning on 02/10/2024.